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ABSTRACT
Gentamicin is a widely-used antimicrobial agent for obstetric and gynecologic infections. Renewed
excitement in this antibiotic has arisen from recent information supporting less frequent dosing. In
this symposium, we will describe the pharmacokinetics of gentamicin and review new information
advocating the use of once-daily administration of gentamicin. Infect. Dis. Obstet. Gynecol. 6:155-
159, 1998. (C) 1998 Wiley-Liss, Inc.
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minoglycosides, discovered over half a century
ago, remain among the most frequently pre-
scribed antibiotic agents for serious infections.
Aminoglycosides are an important component of
the obstetrician-gynecologist’s armamentarium for
obstetrical, gynecological, and postoperative infec-
tions. Gentamicin is the most widely used
aminoglycoside in these settings, and thus will be
the focus of this paper. While aminoglycosides
have been in use for several decades, recent infor-
mation supporting the administration of these
agents once a day has brought renewed interest in
this "older" class of compounds for this modern,
cost-conscience medical era.
STRUCTURE AND DERIVATION
Gentamicin is a fermentation product derived from
the soil actinomycetes Micromonospora purpurea
and Micromonospora echinospora. All aminoglyco-
sides are comprised of an essential six-membered
ring with amino-group constituents bound to at
least two sugar moieties. Gentamicin is soluble in
water but insoluble in organic solvents, thereby re-
stricting permeability across the lipid-rich cell
membranes.
MECHANISM OF ACTION
Antimicrobial activity is achieved following a mul-
tistep process that involves binding to the cell sur-
face, uptake into the intracellular compartment,
and, finally, binding and interaction with ribo-
somes. Gentamicin binds passively to lipopolysac-
charides, phospholipids, and other protein constitu-
ents of the outer membrane of gram-negative bac-
teria. This binding causes disruption of the outer
membrane, resulting in increased permeability of
the cell wall. Uptake of gentamicin subsequently
occurs by energy-dependent processes. Genta-
micin remains intracellular, with intracellular con-
centrations far greater than those found in the ex-
tracellular space. The final step culminating in
antimicrobial activity occurs with binding of gen-
tamicin to the bacterial ribosome (between the
smaller [30S] and larger [50S] subunits), resulting
in misreading of messenger RNA and impaired
protein synthesis.
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PHARMACOKINETICS
Gentamicin, as all aminoglycosides, is administered
by the parenteral route (intravenously or intramus-
cularly) and is poorly absorbed when taken by
mouth. Its high water solubility enables wide dis-
tribution in the vascular and interstitial spaces. The
volume of distribution (Vt)) is 0.2-0.3 L/kg but may
be greater in patients with severe infections. The
half-life (T1/z) of gentamicin is 2 +- hours. Elimi-
nation occurs almost entirely by the kidney, where
it is excreted unchanged with minimhl reabsorp-
tion. Urinary concentration typically exceeds peak
plasma levels during administration, and urinary
levels following a single dose surpass therapeutic
levels for several days.
The pharmacokinetics of gentamicin involve
three phases. Following parenteral administration,
the drug is distributed from the intravaseular to the
extravascular space over 15 to 30 minutes. During
the second phase, gentamicin is excreted into the
kidneys, a process related to glomerular filtration
rate, with the resultant half-life closely dependent
on renal function. The final phase involves the ex-
cretion of gentamicin from renal tissue.
Gentamicin is widely used in obstetrics and gy-
necology, as gram-negative organisms are fre-
quently implicated in reproductive tract infections,
either alone or as part of a polymicrobial process.
Gentamicin is often selected to treat chorioamni-
onitis, postpartum endometritis, pyelonephritis,
pelvic inflammatory disease, and tuboovarian ab-
scesses. Among obstetric patients there are wide
variations in gentamicin elimination, posing diffi-
culties in dose calculation. Using a dose of mg/kg
every 8 hours, Duff et al. found that one-third of
women with postpartum endometritis had sub-
therapeutic levels of gentamicin. Zaske et al. es-
timated that 49% of patients receiving standard
doses of gentamicin would have subtherapeutic
levels, z Establishing therapeutic levels required a
wide range of doses of gentamicin (3.0 to 11.6 mg/
kg/d). Given the wide variation of doses among
obstetric patients, when multiple daily dosing of
gentamicin is used, serum concentrations should
be monitored in patients who do not quickly re-
spond to therapy.
SIDE EFFECTS
The clinician’s main concern regarding the use of
gentamicin (and other aminoglycosides) is the risk
of toxicity, specifically nephrotoxicity and ototox-
icity. The incidence of nephrotoxicity is between 5
and 10% and is even less frequently seen in other-
wise healthy individuals receiving gentamicin.
Risk factors for nephrotoxicity include older age,
multisystem disease, preexisting renal disease, con-
comitant administration of nephrotoxic agents (eg,
cis-platinum, amphotericin-B), and multiple daily
dosing (see below). Aminoglycoside-related neph-
rotoxicity rarely results in severe renal compromise
requiring dialysis. Gentamicin should be discontin-
ued if nephrotoxicity occurs; resolution of renal
function will subsequently follow over several
days. When it is ill-advised to stop aminoglycoside
administration, the dosage should be adjusted to
reduce the risk of increasing toxicity.
SPECTRUM OF ACTIVITY
Gentamicin is active against the majority of gram-
negative bacteria, such as Escherichia coli, Klebsiella
sp, Proteus mirabilis, Citrobacter sp, Serratia sp, En-
terobacter sp, Hemophilus influenzae, and some strains
of Pseudomonas aeruginosa. It possesses some activ-
ity against gram-positive organisms, particularly
methicillin-susceptible Staphylococcus aureus. Gen-
tamicin is not active against anaerobic organisms.
RESISTANCE
Resistance against aminoglycosides occurs by sev-
eral mechanisms, including enzymatic alteration of
the aminoglycoside by aerobic gram-negative bac-
teria, altered bacterial uptake, and by modification
of ribosomal binding sites. Resistance of a particu-
lar organism to gentamicin is slow in development,
therefore resistance rarely emerges during a thera-
peutic course of gentamicin. Resistance to genta-
micin is observed in many strains of enterococci,
Pseudomonas aeruginosa, and methicillin-resistant
Staphylococcus aureus.
ONCE-DAILY DOSING OF GENTAMICIN
Recently developed broad-spectrum antimicrobial
agents (eg, cephalosporins and fluoroquinolones)
with less frequent dosing requirements and favor-
able safety profiles have supplanted aminoglyco-
sides in many clinical settings. However, over the
years new information on the pharmacokinetic
properties and killing parameters of gentamicin
have enabled the development of alternative, less
frequent dosing regimens with lower risk of toxic-
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ity. Aminoglycosides possess concentration, or
dose-dependent killing properties, with greater
bacteriocidal activity associated with higher con-
centrations of drug (eg, 10 times the minimum in-
hibitory concentration [MIC]). This contrasts with
13-1actam agents that possess time-dependent kill-
ing, where maximum antibacterial activity occurs
during prolonged periods of drug concentration
above the MIC. Additionally, gentamicin has a
"postantibiotic effect" (PAE), which is defined as
persistent bacterial growth inhibition after antibi-
otic exposure has ceased. In vitro and animal stud-
ies have documented equivalent or greater antimi-
crobial activity with once-daily dosing versus
smaller, more-frequent doses of aminoglyco-
sides.3,4 The PAE of aminoglycosides pertains to
several different microbial species, and the higher
the initial aminoglycoside level, the greater the
PAE. Both the PAE and the concentration-
dependent killing properties of aminoglycosides
are the rationale behind the utilization of once-
daily dosing of gentamicin. Specifically, the single
large daily dose maximizes bacterial killing, while
the PAE during the extended dosing interval,
when the drug level in the serum is low, would
either allow for ongoing killing or at least prevent
regrowth of bacteria.
There has been a rapid accumulation of pub-
lished trials of once-daily dosing of aminoglyco-
sides, including netilmicin, amikacin, and gentami-
cin. A small randomized study comparing once-
and thrice-daily dosing of gentamicin or netilmicin
in sixty patients demonstrated similar efficacy, but
the study was limited by small sample size.s Prins
et al. compared once-daily dosing of gentamicin,
using a dose of 4 mg/kg/d, to thrice-daily doses of
1.33 mg/kg of gentamicin among 67 adult patients
with serious infections. Once-daily dosing was as
effective as thrice-daily doses, with favorable clini-
cal outcomes seen in 91% of patients receiving
once-daily dosing and in 78% of those receiving
conventional dosing.6 Similar results have been ob-
tained with netilmicin and other aminoglycosides. 7
Metaanalyses have repeatedly demonstrated equal
efficacy of once-daily dosing of aminoglycosides
compared with multiple daily dosing in both clini-
cal and microbiologic cure rates.8-1z Additional
studies are needed among certain populations, par-
ticularly pregnant women, children, and patients
with endocarditis.
Toxicity studies of once-daily dosing of
aminoglycosides have not revealed an increased
risk of either nephrotoxicity or ototoxicity. While
aminoglycosides are accumulated in the renal cor-
tex, the uptake is saturable, with greater accumu-
lation occurring in continuous or divided-dose in-
fusions than in one large dose. Less nephrotoxicity
was observed in laboratory animals receiving once-
daily dosing. In a review of once-daily aminoglyco-
side administration to over 2,000 adult patients,
nephrotoxicity was observed in 1.2% of patients,
and only three patients exhibited clinical ototoxic-
ity.
13 Prins et al. noted significantly less nephrotox-
icity in patients with serious infections receiving
the once-daily dose of gentamicin compared with
thrice-daily dosing (5% vs. 24%, P 0.016) and no
difference in ototoxicity as assessed clinically and
by audiometry.
6 Similarly, several metaanalyses of
single daily dosing of aminoglycosides failed to
demonstrate increased nephrotoxicity or ototoxic-
ity.8,9,1,1z However, in patients with preexisting
renal failure, there are limited data on the safety of
once-daily dosing.
A consensus is lacking regarding the timing, and
even utility, of monitoring aminoglycoside levels.
After 48 hours of therapy, Prins et al. obtained
trough levels immediately preceding and peak lev-
els 30 minutes following the next dose.6 The dose
was subsequently lowered when the trough levels
were above 2 rag/L; no adjustment was made for
peak levels. In a large series of adult patients re-
ceiving once-daily aminoglycosides (mostly genta-
micin), Nicolau et al. reported that only 5% of pa-
tients required a dose adjustment.1 Based on his
results, the following patient criteria for withhold-
ing aminoglycoside levels were identified: age less
than 60 years, no concurrent therapy with nephro-
toxic agents, no exposure to contrast media, no re-
quirement for intensive care support, and not
quadriplegics nor amputees. Nonetheless, serum
creatinine was monitored every 2 to 3 days.
Experience with single-dose gentamicin among
general adult populations has been the foundation
for its use for reproductive tract infections. In our
report in this issue of the journal, we evaluated the
pharmacokinetics of once-daily gentamicin in
women with postpartum endometritis.4 Using a
single daily dose of 4.5 mg/kg actual body weight,
peak gentamicin levels were above 10 mg/L, with
consistently low trough levels. Clinical efficacy of
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this regimen in this preliminary study was excel-
lent, with no nephrotoxicity or clinical ototoxicity.
A recently published randomized trial of once-daily
(5 mg/kg/d) vs. 8-hour dosing (1.75 mg/kg every 8
hours) of gentamicin for the treatment of postpar-
tum endometritis demonstrated equal efficacy and
cost savings with the once-daily regimen,
is Mitra et
al. reported on once-daily gentamicin with twice-
daily clindamycin versus gentamicin and clindamy-
cin each administered three times a day for puer-
peral endometritis. The less-freqtent dosing
schedule was associated with similar outcomes to
those with conventional dosing.
16 Given the diffi-
culty in establishing therapeutic levels with mul-
tiple daily doses in obstetric patients, once-daily
dosing of gentamicin is appealing in this popula-
tion. There are no data on once-daily gentamicin
for gynecologic infections, although this regimen is
becoming widely used in many centers. Similarly,
once-daily dosing has not been well studied in
pregnant women. Its safety in breastfeeding
women remains to be established, however infant
absorption from breast milk should not be a con-
cern due to the inability of gentamicin to be ab-
sorbed from the gastrointestinal tract. There are
limited data on the utility of performing routine
peak and trough levels. As noted above, levels are
likely unwarranted in otherwise healthy adults re-
ceiving once-a-day gentamicin for limited periods
of time.
COST
Once-daily dosing of gentamicin offers important
cost savings over traditional dosing schedules. Re-
duced costs are realized by a reduction in labor
costs, particularly in pharmacist time and nursing
labor, and material costs (intravenous tubing and
bags). In contrast to the thrice-daily regimen,
single-daily dosing does not require monitoring se-
rum levels of gentamicin, resulting in further cost
savings. We calculated a 44% reduction in patient
charges with once-daily dosing of gentamicin for 72
hours of therapy. 14 Substantial cost savings were
similarly noted in the studies by Del Priore et al.
and Mitra et al. as,16
SUMMARY
Gentamicin remains a widely used antibiotic for
treating obstetric and gynecologic infections be-
cause of its activity against gram-negative organ-
isms. Among obstetric patients, serum levels are
varied, requiring monitoring of serum gentamicin
concentrations to ensure therapeutic levels. There
is substantial evidence among general adult popu-
lations documenting equal efficacy and reduced
toxicity with once-daily dosing compared to stan-
dard multidose regimens. Limited data support the
use of single-daily dose gentamicin for the treat-
ment of postpartum endometritis. Using this famil-
iar antibiotic in a new way results in an equally
effective, safer, and less costly approach to the
treatment of gram-negative infections.
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